The lactic acid bacteria preparation designated as veterinary-grade API is a viable, dried microbial ingredient manufactured as a defined single-strain or multistrain blend for incorporation into tablets, capsules, powders, granules, premixes, solutions, and—under restrictive conditions—injectable preparations. The material is not a finished feed additive; it is released under veterinary active pharmaceutical ingredient controls that include strain identity, viable count, water activity, residual moisture, bile tolerance, and absence of specified pathogens. Model identifiers such as LBP-V-01-L, LBP-V-02-S, and LBP-V-03-G are manufacturer-defined and typically encode the production strain, carrier, and drying route; the suffix denotes lyophilization, spray drying, or granulation rather than pharmacopoeial grade. The primary route of administration is oral, with the API standardized to a specified colony-forming unit count per dose. Differences from feed-grade probiotics concern documentation, environmental monitoring, analytical release, and pharmaceutical excipient compatibility.

What release specifications govern viable count, moisture, and microbial purity?

Release testing follows the same microbial enumeration framework used for non-sterile veterinary oral preparations. Total aerobic microbial count is evaluated according to Ph. Eur. 2.6.12 or USP <61>; specified pathogens such as Salmonella and Escherichia coli are evaluated according to Ph. Eur. 2.6.13 or USP <62>. Because the intended bacteria are themselves viable, the total aerobic count method must be read alongside strain-specific enumeration on selective agar. No single pharmacopoeial monograph covers all strain blends; therefore, the release specification for viable count is established from process capability and stability data under VICH GL2 validation. Typical dried veterinary probiotic APIs are released at not less than 1 × 10¹⁰ CFU/g for freeze-dried powders and not less than 1 × 10⁹ CFU/g for spray-dried ingredients, but these values are manufacturer-specific. Loss on drying is commonly controlled below 5.0% w/w and water activity below 0.20 to limit metabolic activity during storage.

Strain identity is confirmed by 16S rRNA gene sequencing or species-specific PCR before blending. Production-scale fermentation under anaerobic or microaerophilic conditions uses MRS or customized whey-based media; pH is maintained at 5.5–6.5 with sodium hydroxide or ammonium hydroxide, and temperature between 30°C and 37°C. Batch-to-batch variance in viable count is influenced by harvest time, centrifugation shear, and lyoprotectant composition. Centrifugal harvest at high g-force can rupture cell walls; therefore, low-shear disk-stack separators and 10% skim milk or trehalose cryoprotectants are used before freeze-drying. Spray drying without cryoprotectant can reduce viable count by 1–3 log₁₀ CFU/g compared with lyophilization, but the exact reduction is strain-dependent. These process variables define the difference between a pharmaceutical-grade API and a less controlled feed additive.

Compaction shear and granulation dynamics in tablet and premix forms

Tableting imposes mechanical stress on dried lactic acid bacteria. Direct compression with microcrystalline cellulose at compression pressures above 150 MPa can reduce viable count by more than 1 log₁₀ CFU/g; the actual loss depends on particle size distribution, moisture, and the lyoprotectant matrix. Granulation with aqueous binder introduces water that can reactivate metabolism and accelerate death; therefore, wet granulation is restricted to low-moisture granulating fluids such as isopropanol or to dry granulation by roller compaction. Roller-compacted granules retain viability better than wet-massed granules when the powder is blended with pregelatinized starch and croscarmellose sodium. For premix forms, the API is dispersed on calcium carbonate, dextrose, or rice hull carriers. Segregation can occur if the particle size difference between API and carrier exceeds 200 µm; the API should be milled to a volume mean diameter of 75–150 µm before dry blending. Blend uniformity is evaluated according to Ph. Eur. 2.9.40 or USP <905>; acceptance is typically 90–110% label claim with RSD ≤ 5.0%. Given tableting moisture sensitivity, pre-drying of excipients to water activity below 0.15 is required when relative humidity exceeds 60% in the compression suite.

Capsule filling with low-speed dosator machines reduces viable count loss relative to high-speed tamping pin machines because tamping pins generate localized shear and heat. For powder administration, the API is often dry-blended with maltodextrin or lactose monohydrate to standardize viable count to a target such as 1 × 10⁹ CFU/dose; the blend is then filled into sachets under nitrogen. Sachet forms require moisture-barrier packaging: polyethylene terephthalate/aluminum foil/polyethylene laminates with oxygen transmission rate below 0.5 cm³/m²·day and water vapor transmission rate below 0.1 g/m²·day at 38°C/90% RH are used to maintain viability during shelf life. Desiccant inclusion is required when water activity exceeds 0.10 at the time of filling.

When injectable or solution dosage forms are requested

Liquid presentation of viable lactic acid bacteria is constrained by metabolic acid production and osmotic stress. If the product is prepared as an oral solution or drench, it should be reconstituted immediately before administration because viability declines rapidly in water at ambient temperature; published data for this specific configuration is limited, but losses exceeding 1 log CFU/mL within 24 h are commonly observed in unbuffered suspensions. Injectable administration is not a standard route for live bacterial preparations. Sterile filtration would remove the bacteria, and terminal sterilization by moist heat or gamma irradiation would inactivate them; therefore, injectable lactic acid bacteria preparations are not generally feasible without sacrificing the intended viable activity. If the dosage form is an injectable product, the API must meet sterility under Ph. Eur. 2.6.1 or USP <71>, bacterial endotoxin limits under Ph. Eur. 2.6.14 or USP <85>, and particulate matter limits under Ph. Eur. 2.9.19 or USP <788>. These requirements conflict with viability retention; the commercial specification should therefore be based on in vitro potency after aseptic processing only, not on terminal sterilization.

For liquid oral products, glycerol and phosphate buffers at pH 6.0–6.8 reduce osmotic damage, but storage at 4°C is required. The product should not be combined with amine-based preservatives such as benzalkonium chloride, which disrupts the bacterial cell membrane and can reduce viable count by more than 3 log CFU/mL within 1 h; this incompatibility is critical in preserved solutions.

Strain identity and batch-to-batch variability across production-scale fermenters

Production-scale variability is driven by the geometry of anaerobic fermenters. In vessels with working volumes from 500 L to 5,000 L, pH gradients around alkali addition ports can generate localized osmotic stress and lower viable count by 0.5–1.0 log₁₀ relative to laboratory-scale controls. Monitoring of oxidation-reduction potential below −100 mV ensures anaerobic conditions for Lactobacillus acidophilus and Limosilactobacillus fermentum, while Enterococcus faecium tolerates microaerophilic conditions. Strain-specific growth rates differ: enterococci may reach stationary phase in 6–8 h, whereas lactobacilli require 12–18 h under comparable conditions. Multistrain fermentations require staggered inoculation or post-fermentation blending because of competitive exclusion and acid inhibition. The final API therefore is usually produced as separate monostrain powders blended to a defined ratio, rather than co-fermented. This practice reduces cross-batch variation in strain proportion and permits label claims for each strain.

Lyophilized API stored in sealed aluminum pouches under nitrogen shows limited viability loss when the glass transition temperature of the amorphous lyoprotectant matrix remains above 40°C. If storage temperature approaches the matrix glass transition, collapse and cell membrane damage occur. Maltodextrin and trehalose matrices with higher glass transition temperatures are therefore preferred for tropical markets; published data for this specific configuration is limited, but technical bulletins from freeze-dryer manufacturers recommend product temperature below the collapse temperature during primary drying. The API should not be exposed to relative humidity above 60% during dispensing, because hygroscopic matrices can absorb moisture and raise water activity above 0.20 within minutes.

Monostrain and multistrain preparations differ in analytical release complexity

Monostrain preparations allow precise viable count and strain-specific identity testing; multistrain preparations provide broader fermentation inhibition in the intestinal lumen but complicate release testing. When strains are blended after drying, the viable count of each component must be assayed separately on selective media. Enterococcus faecium is recovered on kanamycin aesculin azide agar, whereas lactobacilli require MRS agar under anaerobic incubation at 37°C for 72 h. Co-enumeration on one non-selective medium is not acceptable for API release because growth rates and colony morphologies overlap. The difference between monostrain and multistrain APIs is therefore not only efficacy but analytical complexity and batch release cost.

Veterinary API grade differs from feed additive grade in several controls. Feed probiotics are regulated under feed hygiene frameworks and may be listed under EU Regulation 1831/2003; API grade is manufactured under veterinary GMP and released under marketing authorization specifications. Feed carriers such as wheat bran and limestone are frequently not permitted in pharmaceutical dosage forms; the API uses pharmaceutical excipients such as mannitol, microcrystalline cellulose, and sodium starch glycolate. Human live biotherapeutic products often require anaerobic strain identity and antibiotic resistance profiling under applicable guidance, whereas veterinary APIs focus on target species safety, absence of transferable antimicrobial resistance genes, and compatibility with oral rehydration solutions. The difference is not necessarily strain species but the level of documentation, environmental monitoring, and batch release testing. Co-administration with antibiotics, especially ionophores and beta-lactams in feed, can reduce viable count; the product should not be incorporated into premixes containing monensin or salinomycin without compatibility data. For tablet and capsule formulations, avoid direct blending with hygroscopic acidulants such as citric acid monohydrate unless the blend is sealed rapidly, because localized pH below 4.0 reduces viability. The API should not be substituted for feed-grade material in a pharmaceutical dossier without repeating stability and release testing.